C-Myc inhibition sensitizes pre-B ALL cells to the anti-tumor effect of vincristine by altering apoptosis and autophagy: Proposing a probable mechanism of action for 10058-F4-Reference-Cited by-同舟云学术

C-Myc inhibition sensitizes pre-B ALL cells to the anti-tumor effect of vincristine by altering apoptosis and autophagy: Proposing a probable mechanism of action for 10058-F4

Published:2020-03 Issue: Volume:870 Page:172821
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Sheikh‐Zeineddini Negar,Safaroghli-azar Ava,Salari Sina,Bashash Davood

Funder

Shahid Beheshti University of Medical Sciences

Publisher

Elsevier BV

Subject

Pharmacology

Reference38 articles.

1. Small molecule inhibitor of c-Myc 10058-F4 inhibits proliferation and induces apoptosis in acute leukemia cells, irrespective of PTEN status;Bashash;Int. J. Biochem. Cell Biol.,2019

2. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer;Carabet;Eur. J. Med. Chem.,2018

3. Vincristine-induced neuropathy as the initial presentation of Charcot-Marie-Tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study;Chauvenet;J. Pediatr. Hematol./Oncol.,2003

4. The c-Myc Target Gene Network, Seminars in Cancer Biology;Dang,2006

5. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells;Derenne;Blood,2002

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination Drug Strategies for Targeting Specific Biochemical Pathways for Superior Therapeutic Potency;Advances and Prospects of 3-d Metal-Based Anticancer Drug Candidates;2024

2. Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application;Haematologica;2023-09-28

3. Fighting Carcinogenesis with Plant Metabolites by Weakening Proliferative Signaling and Disabling Replicative Immortality Networks of Rapidly Dividing and Invading Cancerous Cells;Current Drug Delivery;2023-05

4. The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin’s lymphoma tumor growth by promoting apoptosis and autophagy;Cell Communication and Signaling;2023-01-23

5. Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies;Pharmacological Research;2022-10